Compare APMD & MMI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | APMD | MMI |
|---|---|---|
| Founded | N/A | 1971 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2026 | 2013 |
| Metric | APMD | MMI |
|---|---|---|
| Price | $26.40 | $31.40 |
| Analyst Decision | | Sell |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $28.00 |
| AVG Volume (30 Days) | ★ 380.2K | 107.0K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | ★ 1.78% |
| EPS Growth | N/A | ★ 84.38 |
| EPS | N/A | ★ 0.02 |
| Revenue | N/A | ★ $719,700,000.00 |
| Revenue This Year | N/A | $14.04 |
| Revenue Next Year | N/A | $11.35 |
| P/E Ratio | ★ N/A | $1,583.00 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $20.02 | $24.43 |
| 52 Week High | $35.29 | $33.62 |
| Indicator | APMD | MMI |
|---|---|---|
| Relative Strength Index (RSI) | 48.62 | 46.01 |
| Support Level | $23.98 | $29.69 |
| Resistance Level | $30.34 | $32.34 |
| Average True Range (ATR) | 3.25 | 0.77 |
| MACD | -0.41 | -0.10 |
| Stochastic Oscillator | 9.43 | 7.34 |
Apnimed Inc is a late clinical-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep related breathing diseases. The company's flagship product candidate, AD109, or Oxnimbi, is an investigational, fixed-dose oral combination of a novel anti-muscarinic and selective norepinephrine reuptake inhibitor for the treatment of obstructive sleep apnea (OSA).
Marcus & Millichap Inc is a national brokerage firm specializing in commercial real estate investment sales, financing, research, and advisory services. The company offers three primary services to its clients: commercial real estate investment brokerage, financing, and ancillary services, including other research, advisory, and consulting services. The company generates revenues by collecting fees on the sale and financing of commercial properties. These fees consist of commissions collected upon the sale of a property and fees collected from the placement of loans. The Company has one reportable segment: commercial real estate services. The commercial real estate services segment is the aggregation of our two operating segments: investment sales and financing services.